Funders › NY › Emerald Foundation Inc Co Solomon Blum Heymann › 2022
Grants paid by Emerald Foundation Inc Co Solomon Blum Heymann, tax year 2022
EIN 13-3912580 · New York, NY · Form 990-PF, Part XV · NTEE T20J
In tax year 2022, Emerald Foundation Inc Co Solomon Blum Heymann (EIN 13-3912580) reported 19 grants paid totaling $1,190,000. Dataset version 2026.09.0, built 2026-09-03.
Every grant, 2022
| Tax year | Recipient | Match | Amount | Type | Purpose | Source filing |
|---|---|---|---|---|---|---|
| 2022 | Weill Med College of Cornell U New York, NY | U | $150,000 | paid | TO IDENTIFY REGULATORS OF LINEAGE REVERSION THAT IMPACT RESISTANCE TO WNT-TARGETED THERAPIES IN COLORECTAL CANCER. | 202303209349101450 |
| 2022 | Ma Institute of Technology Cambridge, MA | U | $150,000 | paid | TO ENHANCE NANOPARTICLE ACCUMULATION IN DESIRED CELL TYPES TO DEVELOP MORE EFFECTIVE AND SAFER TARGETED NANOTHERAPIES. | 202303209349101450 |
| 2022 | Dana-Farber Cancer Institute Boston, MA | B | $100,000 | paid | TO MAP THE TRANSCRIPTIONAL AND PROTEIN CHANGES INDUCED BY LACTATE AND IDENTIFY THE MECHANISMS THAT CAUSE NK SUPPRESSION, ON BOTH NK AND TUMOR CELLS, USING HIGH-THROUGHPUT AND UNBIASED APPROACHES. | 202303209349101450 |
| 2022 | University of Guelph East Guelph, ONTARIO | U | $100,000 | paid | TO IDENTIFY COMBINATIONS OF COMMERCIAL BACTERIAL ISOLATES THAT SUPPRESS KLEBSIELLA PNEUMONIAE IN THE COLON AND THE UNDERLYING COOPERATIVE MECHANISMS OF THIS ACTIVITY. | 202303209349101450 |
| 2022 | Ca Institute of Technology Pasadena, CA | U | $80,000 | paid | TO DEVELOP INTERPRETABLE MACHINE LEARNING METHODS THAT LINK SPATIAL PHENOTYPES IN IMAGING DATA OF SOLID TUMORS WITH PATIENT OUTCOMES. | 202303209349101450 |
| 2022 | University of Md Baltimore Foundati Baltimore, MD | U | $75,000 | paid | TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | 202303209349101450 |
| 2022 | Rockefeller University New York, NY | B | $75,000 | paid | TO INVESTIGATE THE ROLE OF TRNA-DERIVED FRAGMENTS AND THE GENES THEY REGULATE IN BREAST CANCER PROGRESSION AND METASTASIS. | 202303209349101450 |
| 2022 | University of Md Baltimore Foundati Baltimore, MD | U | $75,000 | paid | TO INVESTIGATE THE REGULATION OF TREG LYMPHATIC TUMOR MIGRATION AND THE INTERACTION AMONG TREGS, LYMPHATIC ENDOTHELIAL CELLS, AND TUMORS TO DEVELOP STRATEGIES OF DELIVERING TARGETED THERAPIES LOCALLY INSTEAD OF SYSTEMICALLY. | 202303209349101450 |
| 2022 | Whitehead Institute for Biomed Cambridge, MA | D | $50,000 | paid | TO UNCOVER THE SET OF CELL-SURFACE PROTEINS THAT MEDIATE ESSENTIAL INTERACTIONS BETWEEN PDAC CELLS AND THEIR MICROENVIRONMENT. | 202303209349101450 |
| 2022 | John Hopkins University Baltimore, MD | U | $50,000 | paid | TO INVESTIGATE HOW THE COLON MICROBIOTA AND HOST GENETICS INTERSECT TO ALTER RESPONSIVENESS TO IMMUNOTHERAPY IN COLORECTAL CANCER. | 202303209349101450 |
| 2022 | Salk Institute for Bio Studies La Jolla, CA | C | $50,000 | paid | TO USE INNOVATIVE CELL BIOLOGY TECHNIQUES COUPLED WITH GENOMICS TO INVESTIGATE THE ROLE OF MITOCHONDRIAL-DERIVED VESICLES IN CANCER CELL METABOLISM. | 202303209349101450 |
| 2022 | Ma Institute of Technology Cambridge, MA | U | $37,500 | paid | TO DEVELOP A HIGH-THROUGHPUT SINGLE-CELL GRO-SEQ ASSAY TO EXAMINE THE TUMOR MICROENVIRONMENT ESTABLISHED BY MUTANT-P53 AND DECIPHER THE GENE REGULATORY NETWORKS UNDERLYING PDAC'S INTRASIGENCE TO IMMUNOTHERAPIES. | 202303209349101450 |
| 2022 | Institute for Cancer Research Philadelphia, PA | C | $37,500 | paid | TO INVESTIGATE THE ROLE OF BRG1-DEPENDENT EPIGENETIC REGULATION ON PDAC FIBROBLAST PRO-TUMORIGENIC FUNCTIONS. | 202303209349101450 |
| 2022 | Ma Institute of Technology Cambridge, MA | U | $37,500 | paid | TO DEVELOP A HIGH-THROUGHPUT SINGLE-CELL GRO-SEQ ASSAY TO EXAMINE THE TUMOR MICROENVIRONMENT ESTABLISHED BY MUTANT-P53 AND DECIPHER THE GENE REGULATORY NETWORKS UNDERLYING PDAC'S INTRANSIGENCE TO IMMUNOTHERAPIES. | 202303209349101450 |
| 2022 | University of Ky Lexington, KY | U | $37,500 | paid | TO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | 202303209349101450 |
| 2022 | John Hopkins University Baltimore, MD | U | $37,500 | paid | TO USE TUMOR ORGANOID AND MOUSE MODELS TO DETERMINE HOW LOSS OF CLAUDIN PROTEINS IMPACTS TUMOR INVASION AND METASTASIS. | 202303209349101450 |
| 2022 | University of Ca Santa Barbara Santa Barbara, CA | B | $37,500 | paid | TO UNDERSTAND HOW MALADAPTIVE CHANGES TO THE INTEGRATED STRESS RESPONSE PATHWAY ALTER THE FORCE GENERATING ABILITY OF HUMAN HEART CELLS AND DETERMINE IF PHARMACOLOGICAL MANIPULATION CAN RESCUE CARDIOMYOCYTE FUNCTION. | 202303209349101450 |
| 2022 | Institute for Cancer Research Philadelphia, PA | C | $5,000 | paid | TO INVESTIGATE THE ROLE OF BRG1-DEPENDENT EPIGENETIC REGULATION ON PDAC FIBROBLAST PRO-TUMORIGENIC FUNCTIONS. | 202303209349101450 |
| 2022 | John Hopkins University Baltimore, MD | U | $5,000 | paid | TO INVESTIGATE HOW THE COLON MICROBIOTA AND HOST GENETICS INTERSECT TO ALTER RESPONSIVENESS TO IMMUNOTHERAPY IN COLORECTAL CANCER. | 202303209349101450 |
Match tier: A Reported EIN · B Exact name and place · C Strong name match · D Probable name match · U Unresolved. Tiers C and D are inferred, not reported; see how matching works.
Recipient matching for this dataset version has not yet completed its independent precision check. Tier A rows carry the EIN the filer reported; tiers B–D are the matcher's inference and should be read as leads until the check is published on the methodology page.
Derived from IRS Form 990-PF e-file XML. Dataset version 2026.09.0, built 2026-09-03. All years for this funder.
The same organization elsewhere in the program: exempt status and filing health · federal awards · grant guidance · open opportunities.
This is informational only, derived from public data on the dates shown. It is not an eligibility determination, and not legal, tax, or accounting advice. Verify against the official source before relying on it.